Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PBD C06

Next Previous
Search
Drug Profile

PBD C06

Alternative Names: anti-pGlu3-Abeta monoclonal antibody - Vivoryon Therapeutics; PBD-C06; pGlu-specific mAb - Vivoryon Therapeutics; SIM-0409

Latest Information Update: 29 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Probiodrug
  • Developer Vivoryon Therapeutics
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 23 May 2024 PBD C06 is available for licensing as of 23 May 2024
  • 03 Jan 2024 PBD C06 is still inpreclinical phase for Alzheimer's-disease in USA (Vivoryon Therapeutics pipeline, January 2023)
  • 28 Jul 2023 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top